ALIMERA SCIENCES, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2010-12-23: Form 8-K; Period of report 2010-12-23; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2010-12-07: Form 8-K; Period of report 2010-12-02; Description 8.01 Other Events; Details 8.01.
- 2010-11-04: Form 8-K; Period of report 2010-11-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2010-10-18: Form 8-K; Period of report 2010-10-14; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2010-12-23 | 8-K | 2010-12-23 | 7.01 Regulation FD Disclosure | 7.01 On December 23, 2010, Alimera Sciences, Inc. (“Alimera”) issued a press release announcing that it has received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application for Iluvien® for the treatment of diabetic macular edema. | g25619e8vk.htm |
| 2010-12-07 | 8-K | 2010-12-02 | 8.01 Other Events | 8.01 On December 2, 2010, the following officers of Alimera Sciences, Inc. (the “Company”) adopted prearranged stock trading plans in accordance with the Company’s securities trading policy and the guidelines specified by Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (“Rule 10b5-1”): C. Daniel Myers, President and Chief Executive Officer, Richard S. Eiswirth, Jr., Chief Financial Officer and Chief Operating Officer and David Holland, Senior Vice President of Sales and Marketing. | htm_39990.htm |
| 2010-11-04 | 8-K | 2010-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2010, Alimera Sciences, Inc. (the “Company”) issued a press release and held a conference call regarding its results of operations and financial condition for the third quarter ended September 30, 2010. | g25139e8vk.htm |
| 2010-10-18 | 8-K | 2010-10-14 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Definitive Material Agreement. 2.03 The information disclosed in Item 1.01 above is incorporated herein by reference. 3.02 The Company relied on the exemption from registration contained in Section 4(2) of the Securities Act, and Rule 506 of Regulation D, in connection with the issuance of the Lender Warrants in connection with the Term Loan Agreement. | g24903e8vk.htm |
| 2010-10-06 | 8-K | 2010-10-04 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Definitive Material Agreement. | htm_39260.htm |
| 2010-08-30 | 8-K | 2010-08-30 | 7.01 Regulation FD Disclosure | 7.01 On August 30, 2010, Alimera Sciences, Inc. (the "Company") issued a press release announcing that the Company’s New Drug Application for Iluvien® (fluocinolone acetonide intravitreal insert) has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration. | htm_38879.htm |
| 2010-08-16 | 8-K | 2010-08-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 16, 2010, Alimera Sciences, Inc. (the “Company”) issued a press release announcing the promotions of Richard S. Eiswirth, Jr. to Chief Operating Officer and David R. Holland to Senior Vice President of Sales and Marketing. | g24371e8vk.htm |
| 2010-08-12 | 8-K | 2010-08-12 | 2.02 Results of Operations and Financial Condition | 2.02 On August 12, 2010, Alimera Sciences, Inc. (the “Company”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the second quarter ended June 30, 2010. | g24347e8vk.htm |
| 2010-06-03 | 8-K | 2010-06-03 | 2.02 Results of Operations and Financial Condition | 2.02 On June 3, 2010, Alimera Sciences, Inc. (the “Company”) issued a press release and is holding a conference call regarding its results of operations and financial condition for the first quarter ended March 31, 2010. | g23670e8vk.htm |
| 2010-05-27 | 8-K | 2010-05-27 | 7.01 Regulation FD Disclosure | 7.01 Alimera Sciences, Inc. (the “Company”) issued a press release on May 27, 2010 regarding a presentation that the Company will make at the Citi Health Care Conference in New York, New York on Thursday, May 27, 2010. | g23616e8vk.htm |